Central Macular Topographic and Volumetric Measures: New Biomarkers for Detection of Glaucoma.


Journal

Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919

Informations de publication

Date de publication:
08 07 2022
Historique:
entrez: 29 7 2022
pubmed: 30 7 2022
medline: 3 8 2022
Statut: ppublish

Résumé

To test the hypothesis that newly developed shape measures using optical coherence tomography (OCT) macular volume scans can discriminate patients with perimetric glaucoma from healthy subjects. OCT structural measures defining macular topography and volume were recently developed based on cubic Bézier curves. We exported macular volume scans from 135 eyes with glaucoma (133 patients) and 155 healthy eyes (85 subjects) and estimated global and quadrant-based measures. The best subset of measures to predict glaucoma was explored with a gradient boost model (GBM) with subsequent logistic regression. Accuracy and area under receiver operating curves (AUC) were the primary metrics. In addition, we separately investigated model performance in 66 eyes with mild glaucoma (mean deviation ≥ -6 dB). Average (±SD) 24-2 mean deviation was -8.2 (±6.1) dB in eyes with glaucoma. The main predictive measures for glaucoma were temporal inferior rim height, nasal inferior pit volume, and temporal inferior pit depth. Lower values for these measures predicted higher risk of glaucoma. Sensitivity, specificity, and AUC for discriminating between healthy and glaucoma eyes were 81.5% (95% CI = 76.6-91.9%), 89.7% (95% CI = 78.7-94.2%), and 0.915 (95% CI = 0.882-0.948), respectively. Corresponding metrics for mild glaucoma were 84.8% (95% CI = 72.1%-95.5%), 85.8% (95% CI = 87.1%-97.4%), and 0.913 (95% CI = 0.867-0.958), respectively. Novel macular shape biomarkers detect early glaucoma with clinically relevant performance. Such biomarkers do not depend on intraretinal segmentation accuracy and may be helpful in eyes with suboptimal macular segmentation. Macular shape biomarkers provide valuable information for detection of early glaucoma and may provide additional information beyond thickness measurements.

Identifiants

pubmed: 35904793
pii: 2783522
doi: 10.1167/tvst.11.7.25
pmc: PMC9344219
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

25

Subventions

Organisme : NEI NIH HHS
ID : R01 EY029792
Pays : United States

Références

Arch Ophthalmol. 2006 Feb;124(2):193-8
pubmed: 16476888
Am J Ophthalmol. 2019 Feb;198:136-145
pubmed: 30316669
Ophthalmol Glaucoma. 2021 Nov-Dec;4(6):604-616
pubmed: 33774215
IEEE Trans Vis Comput Graph. 2018 Aug;24(8):2366-2379
pubmed: 28829310
Br J Ophthalmol. 2018 Jun;102(6):718-724
pubmed: 29055905
Clin Exp Optom. 2019 May;102(3):300-308
pubmed: 30983019
Entropy (Basel). 2021 Jun 01;23(6):
pubmed: 34205877
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1774-82
pubmed: 10845598
Ophthalmic Res. 2018;59(3):148-154
pubmed: 28877522
Prog Retin Eye Res. 2017 Mar;57:46-75
pubmed: 28012881
Invest Ophthalmol Vis Sci. 2011 Oct 11;52(11):8094-101
pubmed: 21911590
Invest Ophthalmol Vis Sci. 2013 Jul 01;54(7):4422-9
pubmed: 23722389
J Glaucoma. 2001 Jun;10(3):192-8
pubmed: 11442181
Invest Ophthalmol Vis Sci. 2012 May 04;53(5):2476-81
pubmed: 22562845
Prog Retin Eye Res. 2013 Jan;32:1-21
pubmed: 22995953
Surv Ophthalmol. 2020 Nov - Dec;65(6):597-638
pubmed: 32199939
Invest Ophthalmol Vis Sci. 2014 Jan 29;55(1):612-24
pubmed: 24408977
JAMA Ophthalmol. 2015 Dec;133(12):1438-44
pubmed: 26502216
Biomed Opt Express. 2017 Aug 22;8(9):4181-4199
pubmed: 28966857
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):788-791
pubmed: 29392325
J Chin Med Assoc. 2019 Apr;82(4):335-339
pubmed: 30946212
Ann Clin Transl Neurol. 2021 Jul;8(7):1528-1542
pubmed: 34008926
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 23;7(5):
pubmed: 32576604
Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4772-8
pubmed: 27623333
Transl Vis Sci Technol. 2020 Jun 30;9(7):50
pubmed: 32832255
Comput Biol Med. 2022 Feb;141:104822
pubmed: 34548173
Am J Ophthalmol. 2015 Jul;160(1):53-61.e2
pubmed: 25800454
Ophthalmology. 2017 Sep;124(9):1383-1391
pubmed: 28412067
PLoS One. 2015 May 15;10(5):e0125957
pubmed: 25978420
Am J Ophthalmol. 2013 Dec;156(6):1297-1307.e2
pubmed: 24075422
Curr Opin Ophthalmol. 2009 Mar;20(2):92-8
pubmed: 19240541
Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):4998-5010
pubmed: 30326067
Clin Ophthalmol. 2014 Mar 26;8:611-21
pubmed: 24707166
Ophthalmology. 2012 Jun;119(6):1151-8
pubmed: 22365056
Br J Ophthalmol. 2014 Jul;98 Suppl 2:ii1-9
pubmed: 24934219
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6788-95
pubmed: 26567791
Transl Vis Sci Technol. 2018 Mar 09;7(2):4
pubmed: 29576928
Arch Ophthalmol. 2003 Jan;121(1):41-6
pubmed: 12523883
Optom Vis Sci. 2021 May 1;98(5):518-530
pubmed: 33973920
Am J Ophthalmol. 2002 Aug;134(2):177-85
pubmed: 12140023
J Glaucoma. 2016 Mar;25(3):e196-203
pubmed: 26066503
Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5984-9
pubmed: 26393464

Auteurs

Vahid Mohammadzadeh (V)

Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Melodyanne Cheng (M)

Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Sepideh Heydar Zadeh (SH)

Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Kiumars Edalati (K)

Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Dariush Yalzadeh (D)

Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Joseph Caprioli (J)

Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Sunil Yadav (S)

Experimental and Clinical Research Center, Max Delbruck Center for Molecular Medicine, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Ella M Kadas (EM)

Experimental and Clinical Research Center, Max Delbruck Center for Molecular Medicine, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Alexander U Brandt (AU)

Department of Neurology, University of California Irvine, CA, USA.

Kouros Nouri-Mahdavi (K)

Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH